Senti Biosciences, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for SNTI, updated each market day.
SNTI AI Sentiment
AI sees no strong directional signal for Senti Biosciences, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Senti Biosciences, Inc. Common Stock
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow, and SENTI-301A for the treatment of hepatocellular carcinoma.
Sector
Exchange
Market Cap
$26,946,218
Cap Tier
Employees
39
Headquarters
SOUTH SAN FRANCISCO, CA
Listed Since
June 9, 2022
Website
SNTI Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
SNTI Volatility
Senti Biosciences, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
